Document is current
Any future updates will be listed below
-
Authors
Ouyang, Zhou
Zeng, Ruolan
Wang, Song
Wu, Xiaoying
Li, Yajun
He, Yizi
Wang, Caiqin
Xia, Chen
Ou, Qiuxiang
Bao, Hua
Yang, Wei
Xiao, Ling
Zhou, Hui
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (No. 82204414)
Hunan Provincial Natural Science Foundation of China (No. 2022JJ30789, No. 2022JJ30026)
Precision Diagnosis and Treatment Center for Lymphoma in Hunan Province, Hunan Development and Reform Commission High-tech ([2021]No.1073)
Clinical Research Center for Lymphoma in Hunan Province, Hunan Provincial Clinical Medical Research Center for Lymphatic Tumors (No. 2021SK4015)
National Key Clinical Specialty Construction Project (No. 2023-223)
- License Information
-
More Information
Article History
Received: 28 February 2025
Accepted: 12 April 2025
First Online: 3 May 2025
Declarations
:
: The study was approved by the Ethics Committee of Hunan Cancer Hospital (No. 2024–152). Written informed consent was obtained from each patient before sample collection.
: Not applicable.
: S. Wang, X.Y. Wu, Q.X. Ou, H. Bao, and W. Yang are employees of Nanjing Geneseeq Technology Inc. The remaining authors declare no competing interests.
